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ABSTRACT

Vascular endothelial growth factor (VEGF), a commonly overexpressed oncogene
in a variety of malignancies including non-small cell lung cancer (NSCLC), is a key
regulator of angiogenesis promoting tumor survival, growth, and metastasis. The
promoters of several cancer-related genes, including VEGF, contain disproportionate
sequences within nuclease hypersensitivity regions capable of forming quadruplex (fourstranded) DNA. The specific quadruplex forming sequence of interest is the 20 base pair
polyG/polyC tract that codes for the VEGF promoter (VEGFq), which is located in the
proximal promoter region upstream of the transcription initiation site. This
oligonucleotide has been shown to have significant growth hindering effects when
introduced in the NSCLC cell line, A549.
To determine the biological role of VEGFq on non-small cell lung cancer in vitro,
cells were treated with either VEGFq or the corresponding mutant sequence (MutVEGF),
which lacks the runs of guanines necessary for quadruplex formation. Circular dichroism
spectroscopy confirmed that VEGFq formed a parallel quadruplex, while the MutVEGF
sequence did not form a quadruplex structure. It is hypothesized that the considerable
growth inhibition is caused by hindering the VEGF signaling pathway. The VEGF
signaling cascade, which is normally triggered by VEGF binding to FLK1 (VEGF
Receptor 2), is unable to function adequately due to decreased VEGF protein levels. This
causes a disruption in the phosphorylation of target proteins including ERK1/2 and
AKT/PKB, which in turn decreases overall cell proliferation. This observed decline in
overall cell proliferation corresponded to decreased levels of VEGF protein expression,

v

indicating that there is a direct correlation between the treatment and the changes in
proliferation. A single treatment of A549 NSCLC cells with VEGFq caused a significant
dose and time-dependent decrease in cell viability after 3 and 6 days as determined by
MTT assay. Parallel treatment of nontransformed human fibroblast cells with VEGFq
showed no changes in growth, demonstrating the cancer specificity of VEGFq. Cell cycle
analysis showed no changes in cell phases at 24, 48, 72 and 96 hours, indicating that
VEGFq's effects due to a mechanism other than cell cycle arrest. Confocal microscopy
and flow cytometry after 72 hours showed significant uptake and nuclear localization of
VEGFq, but not MutVEGF. Boyden chamber invasion/migration measurement shows
that the VEGFq treated cells have decreased cell movement, indicative of possible antiangiogenic effects as well.
To determine the biological role of VEGFq on non-small cell lung cancer in vivo,
A549 cells were injected into nude mice and grown for 10 days prior to daily IP
injections of 10 mg/kg VEGFq or the control vehicle for 14 days. Tumor progression was
physically measured using calipers three times a week. Fluorescent imaging was used to
detect the presence, stability, and distribution of Alexa Fluor 750-labeled VEGFq after
injection into the mouse to ensure localization in the targeted tumor.
These results demonstrate that A549 cells treated with VEGF quadruplex-forming
oligonucleotides experience a dramatic decrease in cell proliferation, suggesting that
VEGFq may have significant therapeutic implications for the treatment of non-small cell
lung cancer.
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I. INTRODUCTION

1.1 Lung Cancer and Current Treatments
Lung cancer is a highly prevalent disease with an estimated 250,000 new
diagnoses in 2011 in the US alone and is the leading cause of cancer deaths in the US,
with a staggering 5-year survival rate of only 15.7%. Lung cancer can be broken down
into two subtypes known as small cell lung cancer and non-small cell lung cancer
(NSCLC) depending on the tumor morphology (NCI, 2011). NSCLC comprises 80.4% of
lung cancers and can be further classified as adenocarcinoma, squamous cell carcinoma,
or large cell carcinoma (NCBI, 2011, Travis, 1995). Adenocarcinomas are the most
common form of lung cancer, accounting for 44% of NSCLC, and are typically found in
the outer regions of the lung. Another 37.5% of NSCLC are squamous cell carcinomas,
which are usually found in the center of the lung next to a bronchus. The less common
large cell carcinomas account for the other 18.5%, and can be found in any part of the
lung. Smoking has been identified as the primary cause of most cases of adenocarcinoma
and squamous cell carcinoma; however, it is a common misconception that smoking is
the only way to develop lung cancer. In fact, some people who have never smoked have
gotten lung cancer (NCBI, 2011, Bryant, 2007). Although it is often difficult to pinpoint
what causes each patient’s lung cancer, some common risk factors for NSCLC include
long term exposure to high levels of: air or drinking water pollution, asbestos, coal
products, mustard gas, preservatives, and formaldehyde (NCBI, 2011). Despite lung
cancer research funding of over 281 million dollars in 2010 alone, not much progress has
been made in the way of improving patient survival rates (NCI, 2011).
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Conventional treatment options for non-small cell lung cancer (NSCLC) involve a
long list of regimens, including 1) cytotoxic combination chemotherapy with the
platinum based drugs cisplatin or carboplatin as well as paclitaxel, gemcitabine,
docetaxel, vinorelbine, irinotecan, and pemetrexed; or, 2) bevacizumab and cetuxemab;
or 3) epidermal growth factor receptor tyrosine kinase inhibitors; or, 4) cisplatin,
vinorelbine, and cetuximab; or, 5) maintenance premetrexed; or, 6) external beam
radiation therapy; or, 7) endobronchial laser therapy and/or brachytherapy. The specific
treatment route selected for patients depends on several factors and disease specifics
including but not limited to: tumor histology, patient age versus comorbidity,
performance status, presence, number, and location of metastases, EGFR expression
and/or mutation, and previous treatments received (NCI, 2011). All of these therapies are
accompanied by a number of side effects ranging from mild to severe that are manifested
as a result in damage to patients’ normal cells due to their non-specificity for cancer. The
lethal nature of NSCLC demands that a more effective and selective therapy be
developed to improve outcomes and reduce the burden of unwanted side effects.

1.2 Vascular Endothelial Growth Factor and Its Receptors
The Vascular Endothelial Growth Factors (VEGFs) are a family of five secreted
dimeric proteins capable of acting upon many different cell types, but are mainly
associated with endothelial cell stimulation. VEGF members include VEGFA, VEGFB,
VEGFC, VEGFD, and placenta growth factor (PLGF) that regulate the growth of new
blood vessels in embryos (vasculogenesis), the growth of blood vessels from existing
vasculature (angiogenesis), and overall vascular maintenance in adults (Olsson, 2006).
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Prior to the discovery of the other subtypes, VEGF referred to VEGFA, which is the
primary member of its growth factor family, and the two terms are typically
interchangeable (Loureiro, 2005).
VEGFA is an eight exon long gene located on chromosome 6 that undergoes premRNA splicing to produce proteins from 19 of its 25 unique transcripts; however, only
six of these have been highly classified (ENSEMBL, 2011, Robinson, 2001, Hilmi,
2011). These isoforms are annotated as VEGFxxx, where the xxx represents the number
of amino acids present minus the signal peptide. The most common are 121, 165, and
189, which have been found to exist as an “a” or “b” splice variant. VEGFxxxa forms
arise from the proximal splicing of exon 8, and VEGFxxxb forms are created from the
distal splicing of exon 8. As expected, VEGFxxxa forms have been shown to be proangiogenic. Curiously however, evidence has been found that suggests that VEGFxxxb
forms have an inhibitory effect on angiogenesis (Hilmi, 2011).
VEGF is capable of acting on cells through the binding to its tyrosine kinase
receptors (VEGFR), numbered one through three. These receptors contain seven varying
extracellular immunoglobulin-like domains allowing them to bind different forms of
VEGF with differing affinities. Additionally, they contain conserved trans-membrane
domains, anchoring them to the plasma membrane, and intracellular tyrosine kinase
domains allowing them to participate in signal transduction. VEGFR-1 and VEGFR-2
bind several forms of VEGF, but have the highest affinity for VEGFA. VEGFR-3 does
not bind VEGFA, only the VEGFC and VEGFD forms. Despite its capability to bind
VEGFA, VEGFR-1 activation has no apparent effects on proliferation, migration, or
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cytoskeletal remodeling can be detected. Conversely, VEGFR-2 activation has been
shown to induce these processes (Robinson, 2001).

1.3 VEGF Signaling and Cancer
VEGF is often highly overexpressed in lung cancer and is commonly associated
with poor prognosis, making it an attractive target for therapeutic agents for treatment of
NSCLC (O’Byrne, 2006, Robinson, 2001, Yuan, 2000). In order for VEGF to transmit its
message to cancer cells, a series of signaling steps must occur (Figure 7A). Firstly, VEGF
must be secreted and bind to VEGFR-2 on the target cell, acting through an autocrine or
paracrine mechanism (Mendel, 2000). Receptor binding then stimulates a cascade
through several downstream kinases, notably ERK, p38, and Akt. These kinases then
trigger the up-regulation of proliferation, angiogenesis, vascular permeability, and cell
survival (Kanehisa Laboratories, 2009). These processes have been identified to be
critical for tumor survival, growth, and metastasis of lung cancer (Molina, 2006).
Bevacizumab, a monoclonal antibody to VEGF, is a recent development in
targeted VEGF therapy that has shown promising results in patient studies; however,
patients treated with bevacizumab still experience adverse effects of the drug and even
deaths due to pulmonary hemorrhage, gastrointestinal hemorrhage, central nervous
system infarction, gastrointestinal perforation, myocardial infarction, or neutropenic
sepsis (Cao, 2011, NCI, 2011). VEGF-targeted therapeutics provide an important and
necessary weapon against NSCLC to ensure that the tumor does not receive a blood
supply adequate enough to survive, thrive, and spread to other regions of the body, yet
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improvement upon current VEGF directed therapeutics is necessary to enhance patient
outcomes and reduce treatment related harm.
Another method of inhibiting VEGF-induced tumor growth involves targeting
VEGFR-2 so that cannot transmit its signaling cascade correctly. Two small molecule
tyrosine kinase inhibitors (TKI) being investigated include sorafenib and sunitinib. These
multi-targeted inhibitors do not specifically act upon VEGFR-2; however, they work to
inhibit multiple kinases. Although they both show promise in other types of cancer, they
do not appear to be any benefit to lung cancer patients (Jain, 2006). In fact, the addition
of sorafenib to treatment regimens for squamous cell lung cancer increased patients’ risk
of mortality (Chustecka, 2008). Another TKI that is specific to VEGFR-2 is known as
semaxanib. Despite its advancement to phase III clinical trials in colorectal cancer, it
failed to meet the efficacy goals, and as a result the trials were canceled prior to
completion. Further drug development, including investigation as a treatment for lung
cancer, was not pursued due to these poor results (Jain, 2006). Even though TKI therapies
show promise for some cancer types, it is apparent that this current generation of drugs
do not show enough efficacy for the treatment of NSCLC.

1.4 Oligonucleotide Therapy
One class of gene-specific therapeutic agents that has been examined as a
potential cancer therapy is known as an antisense oligonucleotide. First discovered
around 1980, these naturally occurring single stranded oligonucleotides are
complementary to the RNA sequence of their target. Synthetic antisense drugs have been
created to inhibit the expression of a gene through binding to the targeted sequence,
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inhibiting translation of the gene (Zhang, 2005). While this gene-specific approach aims
to improve upon whole cell effects by only inhibiting the undesired gene, it fails to
exclusively target cancer cells, exhibiting highly toxic side effects in all cells. Some
additional barriers against successful antisense therapy include low serum stability, low
affinity for target molecules, low cellular uptake, and vulnerability to nucleolytic
degradation (Kurreck, 2003). While the concept is promising, the setbacks that
accompany antisense therapy make it an unattractive option for the widespread treatment
of cancer.
Another gene-specific therapeutic agent that has been developed recently is the Gquadruplex forming oligonucleotide. These oligonucleotides are guanine-rich, and
possess four runs of at least three guanines, each separated by between one and seven
bases. Through Hoogsteen hydrogen bonding, four nonadjacent guanines can associate
with one another, forming a guanine tetrad. Furthermore, these guanine tetrads are
capable of stacking upon one another, establishing a G-quadruplex (Gubala, 2004). These
structures occur naturally throughout the human genome, most notably in telomeres,
which are found at the ends of chromosomes, as well as in the promoter regions of an
estimated 43% of all genes, including VEGF. While telomeric G-quadruplex formation is
believed to play a role in the protection of chromosomes, those formed in promoter
sequences are thought to negatively regulate transcription of the downstream gene via
steric blockage (Huppert, 2008). This suggests that G-quadruplexes could be an attractive
agent to selectively inhibit the expression of targeted genes.
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1.5 G-Quaduplex DNA for Cancer Therapy
Until recently, the biological significance of G-quadruplex oligonucleotides has
remained unknown. Just over a decade ago, AS1411, a G-rich oligonucleotide designed
as a control sequence for another oligonucleotide being investigated as an inhibitor of
gene expression in cancer, exhibited strange properties during the initial studies. The
sequence actually caused far greater growth inhibition of the cancer cells compared to the
oligonucleotide being investigated. Focus quickly shifted to determine the reason and
mechanism behind the effects caused by this random sequence. During this investigation,
it was noted that this G-rich sequence overcomes all of the setbacks of conventional
antisense oligonucleotide therapies. Namely, AS1411 is highly resistant to degradation by
serum and cellular nucleases, it is taken up by cells without the use of transfection
reagents, and most importantly, it does not have toxic effects on non-cancerous cells.
Since its initial discovery, AS1411 has been shown to be effective in inhibiting the
growth of over 60 different cancer cell lines. Due to its high reactivity in cancer and low
toxicity to non-transformed cells, it has progressed through phase II clinical trials,
exhibiting promising results in both renal cell carcinoma and acute myeloid leukemia
(Bates, 2009).
The success of AS1411 has inspired an abundance of studies aimed at not only
solving the structure and mechanisms of G-quadruplex oligonucleotides, but to also seek
out other G-rich sequences that can be used as cancer therapies. The promoter regions of
many oncogenes are G-rich and are believed to be capable of being specifically targeted
and suppressed by their own specific sequence through the formation of a G-quadruplex.
One such synthetic G-quadruplex forming oligonucleotide that codes for the promoter
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sequence of the common oncogene c-myc is known as PU27. Treatment of leukemic cells
with PU27 has been shown to selectively kill these malignant cells through down
regulation of c-Myc, while overcoming the same setbacks of antisense therapy that
AS1411 does (Sedoris, 2011). This breakthrough suggests that the targeting of VEGF and
other genes containing G-rich promoter sequences (e.g. c-Myc, HIF-1, Bcl-2, etc) with
their corresponding oligonucleotides may possess therapeutic efficacy as cancer-specific
drugs (Qin, 2008).

1.6 Preliminary Data
The work in this section was not performed by the author, but has been included
to support the author’s hypothesis and rationale for pursuing this study. The preliminary
experiments were performed and analyzed by Dr. Kara Sedoris, Sheila Thomas, Cortney
Clarkson, Campbell Grant, and Dr. Donald Miller at the James Graham Brown Cancer
Center.
In order to identify a molecular target for the treatment of NSCLC with Gquadruplex oligodeoxynucleotides (ODNs), the A549 NSCLC protein expression levels
of common oncogenes containing G-rich promoters (HIF-1, VEGF, BCL-2, and c-Myc)
were determined by Western Blot analysis (Preliminary Figure 1A). After normalizing
each oncoprotein to the housekeeping protein β-actin, VEGF was identified as having the
highest expression out of the four selected proteins, distinguishing it as an attractive
target in A549 cells. Furthermore, the four oncogenes’ Quadruplex-forming ODNs’
effects on cell growth of A549 cells were determined using an MTT assay (Preliminary
Figure 1B). This test elucidated that the VEGF ODN drastically inhibited A549 cell
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growth compared to the other ODNs, perhaps due to the cells’ higher expression of
VEGF. These preliminary findings suggest that the VEGF quadruplex forming ODN
could be a potential therapy for NSCLC, warranting further study and development of
this ODN.

PRELIMINARY FIGURE 1 – Quantitation of the basal protein levels of commonly
overexpressed oncogenes whose promoters are guanine rich and the
changes in growth due to treatment with each respective oncogene’s GQuadruplex ODN in A549 NSCLC.
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1.7 Purpose of Study
The purpose of this study was to determine the biological significance of VEGFq,
the G-quadruplex forming oligonucleotide that codes for the proximal promoter
sequence, as a possible treatment for NSCLC. Characterization of oligonucleotide
secondary structure, quantitation of cell proliferation and invasion, quantitation of
oligonucleotide uptake, localization, and stability, quantitation of changes in protein
expression and phosphorylation, and quantitation of in vivo oligonucleotide activity,
distribution, and stability were performed. Additionally, the data collected in this study
can be utilized to plan future experiments to further model the uptake and action
mechanisms of this novel compound.

1.8 Hypotheses
1) In vitro treatment of NSCLC cells with VEGFq inhibits cell growth and invasion
by decreasing VEGF expression.
2) The in vitro VEGFq-induced decrease in VEGF expression down regulates FLK-1
activation and signaling through downstream kinases.
3) In vivo treatment of xenografted NSCLC cells in nude mice with VEGFq
selectively inhibits NSCLC cell growth.
4) In vivo injection of VEGFq into nude mice xenografted with NSCLC cells
primarily localizes and remains in the tumors compared to non-transformed cells.
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1.9 Significance of the Study
VEGF is a key protein in a variety of cancers including lung cancer that triggers
cells to survive, thrive, and eventually spread to other parts of the body. Inhibition of
VEGF signaling is believed to be an important process in halting lung cancer growth and
metastasis; however, a suitable drug that can accomplish this without causing significant
side effects is yet to be discovered. VEGFq is believed to be capable of filling this void.
Additionally, if current studies are successful, VEGFq may be examined for therapeutic
efficacy in other cancer types in which VEGF is overexpressed. Through the
development and characterization of VEGFq, our group hopes to add another genespecific and cancer-specific agent to the arsenal of next generation oligonucleotides for
utilization in the battle against cancer.
Personalized medicine, or the specific selection of treatment options based upon
the individual patients’ genetic profile rather than the broad treatment of a disease, has
been an attractive yet unrealized idea. This is most likely due to the non-targeted and
globally acting nature of most drugs as well as the unavailability of the necessary genespecific drugs. Without the ability to specifically target genes, personalized medicine
cannot be practiced; however, quadruplex-forming drugs like VEGFq present a possible
opportunity for the development of personalized medicine. Not only does VEGF have a
quadruplex in its promoter sequence, but the promoters of many other oncogenes have
been identified as being capable of forming quadruplexes. Just a few of these include cMyc, c-kit, KRAS, HIF-1, Bcl-2, and RET, with many others yet to be identified and
characterized (Qin, 2008). Through the use of quadruplex drugs that specifically target
and silence these genes in cancer, the practice of personalized medicine may be possible.
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Individual patients’ genomes could be sequenced to identify the key oncogenes activated
in their specific cancer, which will allow physicians to tailor their treatment regiments to
include only the quadruplex drugs needed. Although further investigation and
development of other quadruplex-forming drugs is necessary prior to their widespread
use, this class of cancer drugs theoretically satisfies the current deficiencies of
personalized medicine.
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II. INSTRUMENTATION AND EQUIPMENT

This section contains information regarding the instrumentation and equipment
used during the completion of this thesis.

2.1 Circular Dichroism Spectropolarimeter
Circular Dichroism Spectra were recorded on a Jasco-810 spectropolarimeter
(Jasco, Easton, MD), using a quartz cell of 1 mm optical path length, an instrument
scanning speed of 200 nm/min, response time of 2 sec, and scans were performed over a
wavelength range of 340 nm to 220 nm at room temperature (~25C).

2.2 Spectrophotometer
Absorbances of 96 well plates were determined by using a BioTek Synergy HT
spectrophotometer (BioTek, Winooski, VT). The selected wavelength of light used to
read plates varied depending on experimental conditions.

2.3 Flow Cytometer
Cell cycle and uptake of FITC-labeled ODNs were determined using a FACS
Calibur flow cytometer (BD Biosciences, San Jose, CA). Initial cytometer settings were
optimized for each untreated cell type used, and saved for use during subsequent
experiments to maximize consistency between replicates.
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2.4 Confocal Microscope
Cells were visualized by confocal microscopy with an Olympus Fluoview FV500
(Olympus, Center Valley, PA) laser scanning microscope. A 493 nm laser was used to
visualize the DAPI fluorphore and a 358 nm laser was used to visualize the FITC
fluorophore.

2.5 In Vivo Photon Imager
In vivo uptake and biodistribution of Alexa Fluor 750-labeled VEGFq was imaged
using a Photo Imager RT photon imager, using an excitation wavelength of 750 nm.
Fluorescence integration mode was selected, and a total of 750,000 events were collected
over an acquisition time of 4 seconds to quantitate signal intensity. Images were
generated by capturing 1000 ms per frame.
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III. PROCEDURE

3.1 General
A549

adenocarcinomic

human

alveolar

basal

epithelial

cells,

H1944

adenocarcinomic non-small cell lung cancer cells, H1299 non-small cell lung cancer
carcinoma cells, and Hs27 human fibroblast cells (ATCC) were maintained in DMEM
media supplemented with 10% Fetal Bovine Serum (FBS) and 100 U/mL
penicillin/streptomycin at 5% CO2 and 37 °C. The three lung cancer cell lines were used
to determine the biological significance of the VEGFq oligonucleotide as a potential
treatment for NSCLC while the readily available non-cancerous fibroblast cells were
used as a control for growth inhibition studies to demonstrate VEGFq’s cancer
specificity.
Synthesized oligodeoxynucleotides (ODNs) (Oligos Etc.), delivered as a
lyophilized powder, were reconstituted in RNAse/DNAse free ultrapure DH2O
(Invitrogen) to a stock concentration of 500 µM upon receipt and stored at -20 °C when
not in use. Prior to treatment, the oligonucleotides were thawed at room temperature and
then boiled at 95 °C for 5 min. The boiling is hypothesized to increase the activity of the
oligonucleotides, which is believed to be due to the denaturing of the secondary
structures that formed during cold storage. The VEGFq sequence, which contains runs of
three or more adjacent guanines that are required for quadruplex formation, was the main
oligonucleotide of interest in this study, while MutVEGF was used as an oligonucleotide
control. The general synthesis and preparation methods of both oligonucleotides were
identical; however, their primary sequences differ. MutVEGF is essentially the same
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sequence as VEGFq except that several guanines have been mutated to cytosines so that
it does not contain the runs of three or more adjacent guanines. Without the clusters of
guanines that are necessary for quadruplex formation, it is hypothesized that MutVEGF
does not form a quadruplex. It can then be used as a control in all studies to ensure that
the effects of VEGFq are not simply due to the introduction of foreign DNA, but are
instead sequence specific.
Cells in logarithmic growth phase were plated and treated with 10 µM (final
concentration unless otherwise specified) of VEGFq or the respective control, MutVEGF,
for various time intervals and collected for subsequent biochemical analysis. The ensuing
data was recorded and analyzed using Microsoft Excel, unless otherwise noted.

3.2 Circular Dichroism Spectroscopy
To determine the presence and classification of VEGFq and MutVEGF
oligonucleotide secondary structures, ODNs were boiled for 5 minutes and annealed by
adding physiological buffer containing 20 mM KH2PO4 dibasic, 120 mM KCL, 5 mM
MgCl2 then slow cooled to room temperature. Annealed ODNs were diluted in the same
buffer to approximately 5 µM, a concentration which gives an absorbance of 0.800 at 260
nm according to the spectropolarimeter instructions. Structures of the ODNs in solution
were determined by circular dichroism spectroscopy (CD), using a Jasco-810
spectropolarimeter (Jasco). Three scans were performed for each ODN at 25 °C and then
baseline corrected for signal contributions due to buffer. The spectropolarimeter
determines the difference between the sample’s absorbance of left and right polarized
light at each wavelength. To calculate the molar circular dichroism (Molar CD), which
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can be used to determine ODN secondary structure, the absorbance value was divided by
a provided system constant, the concentration of the sample, the path length, and the
number of bases of the ODN. Each Molar CD value was then plotted versus each
corresponding wavelength. These spectra are representative of the average of the scans
taken.

3.3 MTT Assay
Changes in cell proliferation of lung cancer cell lines and non-transformed
fibroblasts in response to VEGFq or MutVEGF were assessed by 3-(4,5-dimethylthiazol2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Mitochondrial dehydrogenase
activity in viable cells metabolizes MTT into formazan crystals. The concentration of
formazan, which is directly proportional to cell number, can be quantified
spectrophotometrically. A549, H1299, H1944, and Hs27 cells plated in a 96-well plate
(1X103 cells/well) were treated with 1, 3, 5, 10, or 15 µM of either VEGFq or MutVEGF
for 24, 48, 72, 96 h, or 6 days. At the end of the incubation times, 15 µL of MTT reagent
(0.1 µg/µl phosphate buffered saline (PBS)) was added and cells were incubated at 37°C
and 5% CO2. After 4 h, cells were lysed and the formazan product was detected at 570
nm. The optical density of treated wells was standardized to untreated samples in order to
quantify the change in proliferation due to ODN treatment.

3.4 Analysis of VEGFq and MutVEGF Uptake
Cellular uptake of VEGFq or MutVEGF was analyzed by FACS and confocal
microscope image analysis. In order to identify and locate ODNs in these assays, VEGFq
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and MutVEGF were labeled with a 5’ fluorescein isothiocyanate (FITC) tag. FITC is a
green fluorescent molecule whose excitation max is 493 nm and emission max is 517 nm.
A549 or Hs27 cells were incubated with 10 µM of FITC-labeled VEGFq or MutVEGF
for 1, 24, or 72 h before being collected.
For FACS analysis, the cells incubated with FITC-ODNs were first washed with
PBS and then resuspended in 1 mL PBS before being analyzed. The FACS Calibur flow
cytometer (BD Biosciences) was calibrated with untreated cells so that on a forward
scatter versus side scatter plot, the majority of detected cells had mid-range forward and
side scatter. A region was then created that included these cells, which were considered to
be intact and viable cells. Those with very low side scatter and/or very low forward
scatter were excluded, since these cells were most likely dead cells and/or cellular debris,
and would detract from experimental accuracy if included. The cells that fell within the
region of interest (ROI) were gated and further analyzed based on their fluorescent
intensity. This parameter, which was plotted on a fluorescent intensity histogram, was
calibrated so that the untreated cells’ peak occurred very low on the scale, ensuring that
the curve did not make contact with the y-axis. These calibrations were saved and reused
during subsequent experiments for consistency. Each sample was run until 10,000 gated
events were collected. The resulting data was analyzed on Flow-Jo (Tree Star, Inc), and
the presented histograms are representative of three experiments.
For confocal microscopy, Hs27 or A549 cells (grown in 2-well chambered slides)
were treated for 72 h with FITC-labeled VEGFq or MutVEGF. Slides were washed with
PBS, and fixed in 4% paraformaldehyde for 20 min before being washed with PBS again.
Cell nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI), a blue fluorescent
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molecule whose excitation max is 358 nm and emission max is 461 nm. Following
another wash with PBS, slides were mounted with Prolong Gold (Invitrogen) anti-fade
reagent to preserve fluorescence. Cells were visualized by confocal microscopy with an
Olympus Fluoview FV500 (Olympus) laser scanning microscope. Prior to image capture,
laser intensity and gain were optimized and permanently set for FITC and DAPI in order
to minimize background noise while maximizing fluorescent signal without losing
accuracy and precision due to too high of a signal intensity. Samples were visualized at
60X magnification and sequentially scanned with the two lasers to minimize spectral
crossover. The obtained images of FITC only, DAPI only, bright field only and
fluorescent overlay were compiled, and a representative set of each sample was selected.

3.5 Cell Cycle Analysis
A549 or Hs27 cells treated for 24, 48, 72, or 96 h with 10µM VEGFq or
MutVEGF were collected and washed in PBS. Cells were processed with the
CycleTest™ Plus DNA Reagent kit (BD Biosciences), during which they were lysed with
trypsin in spermine teterahydrochloride detergent buffer and the isolated nuclei were
stained with propidium iodide. Prepared nuclei were then analyzed by FACS to
determine the distribution and percentage of cells in each cell cycle phase. For
calibration, similar gating was applied as in the ODN uptake experiments to collect only
the cells with mid-range side and forward scatter. A histogram of fluorescent intensity
was created from 10,000 gated cells. Results were analyzed with Flow-Jo, and the
spectrum provided is a representative of three cell cycle experiments at the 72 h time
point.
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3.6 Serum and Intracellular Stability of VEGFq
VEGFq and MutVEGF sequences were radiolabeled using [-32P]-dATP with T4
polynucleotide kinase (Invitrogen) and incubated at 10 µM in DMEM medium with 10%
FBS or in the presence of A549 cytoplasmic (S100) or nuclear extract at 37 °C for 0, 1, 2,
4, 24, 48, 72, or 96 h. After heating in 98% formamide buffer to 65 °C, ODNs were run
on a 12% denaturing gel and imaged by autoradiography. The obtained images are
representative of three stability experiments.

3.7 Western Blot analysis
To determine the changes in protein expression, A549 cells were incubated with
10 µM of VEGFq or MutVEGF for 24, 72, 96, or 144 h before being collected and lysed.
Samples’ total protein concentrations were determined by Lowry Assay calibrated with
bovine serum albumin (BSA). Equal quantities of A549 total cell lysates were separated
by 4-15% SDS-Tris polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted
onto PVDF membranes. Following transfer, membranes were air dried and then re-wetted
with 100% methanol. Successful electrophoresis and protein transfer was confirmed by
staining with Ponceau S dye. In order to reduce nonspecific binding and background
signal, the membranes were blocked in 5% milk in a solution of 0.05% Tween-20 in PBS
for 1 hr at room temperature with agitation. Membranes were then incubated with
agitation overnight at 4 C with VEGF, ERK1/2, p-ERK1/2, AKT1/2/3, p-AKT1/2/3, or
FLK-1 antibodies (Santa Cruz Biotechnology) diluted in the blocking solution. After
washing three times with 0.05% Tween-20 in PBS for 5 minutes at room temperature, the
membranes were incubated with a horseradish peroxidase (HRP)-conjugated secondary
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antibody diluted in the blocking solution. Following another set of three washes with
PBS-Tween, an additional wash for 5 minutes at room temperature was performed to
remove the detergent. Proteins were visualized by standard chemiluminescence (ECL)
methods (GE Healthcare). All films were scanned with an optical scanner (Epson
Expression 1680) and band densities were quantified using UNSCAN-IT software (Silk
Scientific).
Equal loading of protein samples was verified by probing the membrane with a
mouse monoclonal anti-β-actin primary antibody or a mouse monoclonal anti-GAPDH
primary antibody (Santa Cruz Biotechnology). Prior to re-probing, membranes were
incubated with Restore Western Blot Stripping Buffer (Thermo Scientific) for 15 minutes
at room temperature with agitation and washed with PBS to remove the previously bound
antibodies. To correct for possible unequal loading, each band density was normalized to
its respective β-actin or GAPDH density.

3.8 p-FLK-1 ELISA
To quantify the changes in phosphorylation of VEGFR-2, A549 cells were
incubated with 10 µM of VEGFq or MutVEGF for 72 h before being collected and lysed.
Samples’ total protein concentrations were determined by Lowry Assay calibrated with
BSA. The sandwich ELISA method (R&D Systems) was used to examine 25 and 50 µg
amounts of A549 total cell lysates, according to kit instructions. A 96-well microplate
was incubated overnight at room temperature with a phospho-FLK-1 capture antibody
and washed 5 times with 0.05% Tween-20 in PBS before being blocked with a 1% BSA
in PBS solution for 2 h at room temperature. Following another round of washes, samples
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were diluted to 25 or 50 µg/100 µL in a provided dilution buffer and incubated along
with 4 and 8 ng/mL of a provided phospho-FLK-1 control in separate wells for 2 h at
room temperature. Following another washing step, the plate was incubated with a
phospho-FLK-1 HRP-conjugated detection antibody for 2 h at room temperature. After a
final set of washing, the substrate solution was added, and following a 20 min room
temperature incubation, the stop solution. The resulting absorption was read at 450 nm.
Expression levels were compared to untreated samples to calculate a percent of untreated.
The obtained figure is representative of an average of three experiments.

3.9 Boyden Chamber Invasion/Migration Assay
The Boyden chamber assay was used to assess the metastatic potential of A549
cells in response to VEGFq or MutVEGF. A549 cells pretreated with 10 µM VEGFq or
MutVEGF for 72 h were detached with TripleE (Invitrogen) and seeded (5X105/mL) in
serum-free medium in the top side of the chamber containing an 8 µm pore polycarbonate
filter coated with Matrigel or a control chamber without Matrigel (BD Biosciences).
Medium containing 10% FBS was applied to the lower chamber as a chemoattractant.
VEGFq or MutVEGF (10 µM) were added into the serum-free medium in the top
chamber and the cells were incubated for 24 h at 37°C. At the end of the incubation, cells
in the upper surface of the membrane were carefully removed with a cotton swab and the
cells that had invaded across the Matrigel to the lower surface of the membrane were
fixed with 100% methanol for 2 min, briefly rinsed in PBS, and stained with crystal
violet stain (Sigma-Aldrich) for 2 min. Excess stain was removed by washing in dH2O
before drying overnight at room temperature. Each insert was then imaged at 20X
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magnification using a microscope, and the number of cells present was physically
counted. The percentage of cells that invaded through the Matrigel and migrated through
the filter (percent invasion) was calculated by dividing the number of cells present in
each treatment’s Matrigel chamber by the number of cells present in its respective control
chamber. The invasion index was then calculated by dividing the percent invasion of the
treated cells by the untreated percent invasion.

3.10 VEGFq In Vivo Activity
To determine the in vivo effect of VEGFq on cell proliferation of NSCLC
xenografted in nude mice, 10X106 A549 cells suspended in 100 µL PBS were injected
subcutaneously in each mouse’s left dorsal flank and grown for 10 days. After tumors
became visible under the skin, mice were sorted into groups of small, medium, and large
tumors based on visual inspection of tumor sizes. An equal number of each size set was
then sorted into either the control or treatment groups. The treatment group was then
injected intraperitoneally with 10 mg/kg VEGFq dissolved in an equal volume of 2X
RPMI media for a final volume of 100 µL every weekday until tumor sizes reached a
large enough size that required sacrificing.
Tumor length and width measurements for all animals were collected every other
weekday during the study. The tumor volumes at each time point were calculated by
multiplying the length measurement by the width measurement by one half of the width
measurement. To correct for the differences in beginning tumor sizes, the percent change
in growth was calculated for each animal by dividing the difference between each
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measurement and the initial measurement by the initial measurement, and then averaged
for each group.

3.11 VEGFq In Vivo Stability and Biodistribution
VEGFq stability and biodistribution in the in vivo NSCLC xenograft nude mouse
model was determined by intraorbital injection of 1 mg/kg of Alexa Fluor 750 labeled
VEGFq mixed with an equal volume of 1X RPMI media to a 100 µL final volume for
subsequent imaging. Non-injected control animals were used to establish a baseline for
no fluorescent signal. Treatment and control animals were sedated with isoflurane and
imaged simultaneously in a Photo Imager RT system immediately after injection as well
as at 1, 2, 6, 24, 48, and 72 hour time points. Detector settings were optimized to
minimize background noise while maximizing signal. To quantify the signal coming from
only the tumors, ROIs of equal area that encompassed both the treatment and control
animals’ tumors were selected and a signal strength value was collected. To eliminate the
effect of noise variation on the results, the fluorescence intensity of the control ROI was
subtracted from that of the treatment ROI. This calculation provided a value for the
number of photons per square centimeter due to fluorescently tagged 750-labeled VEGFq
alone being emitted from the tumor due to treatment with VEGFq. These values were
plotted as a function of time to determine the extent of oligonucleotide retention over
time.
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IV. RESULTS AND DISCUSSION OF RESULTS

4.1 VEGFq forms a parallel quadruplex in solution

FIGURE 1 – Representative CD scan of the quadruplex forming oligonucleotide VEGFq
and the non-quadruplex forming oligonucleotide MutVEGF.

To

characterize

the

secondary

structure

of

VEGFq

and

MutVEGF,

oligonucleotides were analyzed using Circular Dichroism spectroscopy, a technique that
has been used to examine the secondary structures of nucleic acids in solution for several
decades (Gray, 2003). VEGFq dissolved in physiological solution had a peak absorbance
at 260 nm and a trough absorbance at 240 nm, indicative of parallel quadruplex formation
(Figure 1). MutVEGF did not form a stable parallel quadruplex in solution, which was
reflected by a shift in its spectrum (Rankin, 2005).
These results confirm that VEGFq can be examined as a quadruplex forming
oligonucleotide, and whose effects can be attributed to this characteristic. Additionally,
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MutVEGF, which arises from the mutation of the VEGFq sequence so that did not have
three adjacent guanines in the sequence, is inhibited from forming a quadruplex;
therefore, it can be used as a negative quadruplex control for VEGFq.

4.2 VEGFq inhibits NSCLC cell proliferation
Treatment of A549 NSCLC cells with 1-15µM VEGFq for 24-144 h caused a
dose and time-dependent decrease in proliferation, culminating to 80% inhibition with 10
µM and 90% inhibition with 15 µM after 6 days compared to untreated cells with an IC50
of less than 5 µM (Figure 2A). Little change in proliferation occurred with MutVEGFq
(Figure 2B). The effect of dose escalation of VEGFq on cell proliferation was also
examined in H1299 (Figure 2C) and H1944 NSCLC cell lines after 72 and 144 h. There
was a significant dose-dependent decrease in cell proliferation with IC50 values of less
than 15 µM after 144 h; however, both cell types were slightly less sensitive than A549
cells. Since the growth arrest occured in the VEGFq treatment groups and not the
MutVEGF groups, these observations suggest that the quadruplex-forming nature of
VEGFq results in decreased cell growth of NSCLC.
Alternatively, treatment of Hs27 non-transformed human fibroblast cells with
VEGFq caused no significant change in cell proliferation (Figure 2D) as compared to
A549 cells treated in parallel. MutVEGF did not affect the growth of either cell line.
These results suggest that growth inhibition due to VEGFq is specific to cancer cells as
compared to normal cells.
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FIGURE 2 – MTT dose response time courses for VEGFq and MutVEGF in A549,
H1299, and Hs27 cells.

4.3 Enhanced cellular uptake of VEGFq
FITC-VEGFq was immediately taken into cells after only 1 hour of treatment,
with enhanced uptake after 24 hours and retained signal at 72 hours post-treatment
(Figure 3A). Significantly less FITC-MutVEGF appeared to be taken into cells at all time
points. Confocal microscopy confirmed these results, showing both cytoplasmic and
nuclear localization of FITC-VEGFq and almost no uptake of MutVEGF at the same
intensity settings (Figure 3B). These results suggest that VEGFq is greatly internalized by
A549 cells compared to MutVEGF and largely located in the nucleus and cytoplasm. A
key improvement of VEGFq upon traditional antisense oligonucleotide therapies is
exhibited here; while antisense oligonucleotides are typically linear and have low cellular
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uptake, the quadruplex secondary structure exhibited by VEGFq may cause the observed
cellular uptake enhancement (Kurreck, 2003).

FIGURE 3 – Cellular uptake and localization of VEGFq and MutVEGF in A549 and
Hs27 cells.
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Similarly, non-transformed Hs27 cells also took up FITC-VEGFq after 1 hour,
with greater uptake over time, which appeared more largely localized in the cytoplasm.
Uptake of VEGFq into Hs27 cells suggest that the anti-proliferative effect of VEGFq on
A549 cells is unrelated to its ability to be taken into cells, but instead may be cancer
specific.

4.4 VEGFq and MutVEGF do not cause a change in cell cycle

FIGURE 4 – Cell cycle analysis of A549 cells treated with VEGFq or MutVEGF.

To determine if treatment of A549 cells with VEGFq or MutVEGF caused an
overall change in the cell cycle, A549 cells incubated with 10μM VEGFq or MutVEGF
for 24-96 h were assessed. No significant change in the cell cycle occurred with VEGFq
or MutVEGF treatment (Figure 4). A representative figure at 72 h is shown; however,
cell cycles at all time points showed similar results.
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4.5 Enhanced VEFGq serum and cytoplasmic stability
Since the therapeutic utility of ODNs is limited by their susceptibility to nuclease
degradation, the stability of VEGFq was examined in serum and intracellularly.
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P-

labeled VEGFq was inherently stable in serum and in the presence of nuclear and
cytoplasmic extracts, while MutVEGF almost immediately degraded into a smaller
product (Figure 5). This remarkable increase in VEGFq stability is likely related to the
inherent nuclease resistance of quadruplex DNA.

FIGURE 5 – Comparison of VEGFq and MutVEGF stability in serum and in cell
extracts.

4.6 VEGFq treatment decreases VEGF protein levels
To determine if VEGFq decreases VEGF protein levels, A549 cells were treated
with 10 μM VEGFq or MutVEGF and analyzed by Western Blotting. Treatment of A549
cells with VEGFq did not decrease VEGF protein levels after 24 and 72 h, however
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caused a marked decrease in expression (< 60% of untreated) after 96 h and 6 days.
MutVEGF treatment did not alter VEGF protein expression levels (Figure 6).

FIGURE 6 – Western Blot results of VEGFq and MutVEGF treated A549 cells.

4.7 VEGFq alters activation of FLK-1 and downstream signaling
Decreased VEGF protein resulting from VEGFq treatment corresponded with a
small decrease in FLK-1 phosphorylation after 72 h compared to untreated A549 cells, as
determined by ELISA analysis (Figure 7C). A less significant change in FLK-1
phosphorylation occurred with MutVEGF treatment. However, total FLK-1 expression
remained constant after either VEGFq or MutVEGF treatment (Figure 7B).
VEGFq treatment of A549 cells slightly decreased total ERK 1/2 levels and
markedly decreased p-ERK 1/2 (p42/p44), beginning at 72 h and continuing thorough 96
h (Figure 7D). Although Akt total 1/2/3 levels remained relatively constant, p-Akt 1/2/3
levels were also significantly decreased after 72 and 96 h by VEGFq (Figure 7E). These
results suggest that the change in phosphorylation of FLK-1 may be due to a decrease in
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binding of VEGF to FLK-1, causing a subsequent decreased in the activity of
downstream kinases ERK and Akt.

FIGURE 7 – Schematic of VEGFR-2 signaling and Western Blot and ELISA analysis of
changes in receptor and downstream protein and phosphorylation levels
due to VEGFq and MutVEGF treatment in A549 cells.

4.8 VEGFq inhibits NSCLC cell invasion
To determine whether decreased VEGF from VEGFq treatment changed A549
cell invasion, cells treated with 10μM VEGFq for 24 h were evaluated by Boyden
chamber analysis. Compared to untreated, VEGFq decreased A549 cell invasion by 40%,
while MutVEGF had no effect (Figure 8). There were no changes in cell number of the
control plates in response to VEGFq or MutVEGF treatment.
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FIGURE 8 – Invasion/Migration analysis of A549 cells treated with VEGFq or
MutVEGF.

4.9 VEGFq inhibits in vivo NSCLC cell proliferation
Following the successful xenografting of A549 cells, nude mice were injected
daily for 14 weekdays with VEGFq, to examine possible growth hindering effects in vivo.
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Even after only two days of treatment, the VEGFq animals’ tumor growth was
significantly arrested compared to the untreated arm (Figure 9). The significant difference
between arms was continued throughout the entire experiment. These results suggest that
VEGFq treatment can inhibit NSCLC tumor growth in vivo.

FIGURE 9 – In Vivo change in tumor growth of xenografted A549 cells treated with
VEGFq or MutVEGF.

4.10 Enhanced VEGFq in vivo stability and tumor localization
To determine the stability and biodistribution of VEGFq in vivo, A549 cells were
xenografted into nude mice and were imaged following an injection of VEGFq tagged
with Alexa Fluor 750. Subsequent quantitation of the fluorescent intensity was performed
to yield a photons/cm2 value. In order to eliminate background noise, the fluorescence
signal (photons/second/cm2) of the untreated mouse’s tumor was subtracted from that of
the mouse treated with VEGFq. This value was multiplied by the acquisition time (4
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seconds), providing a fluorescent intensity per unit area value (photons/cm2). If an
oligonucleotide calibration curve could be created, the fluorescent intensity value could
be used to calculate the concentration of oligonucleotide delivered to the tumor. Results
showed striking uptake of VEGFq into the tumor regions and prolonged storage of
oligonucleotide in the tumor at 72 h after treatment (Figure 10).

FIGURE 10 – In Vivo Alexa Fluor 750 labeled VEGFq fluorescent intensity in
xenografted A549 tumors.
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V. CONCLUSIONS

The following list of conclusions is based upon on the results and analysis of the
experiments performed during this study.



VEGFq forms a stable parallel quadruplex structure under physiological
conditions.



VEGFq significantly inhibits NSCLC cell growth not due to cell cycle arrest with
an IC50 of less than 5 µM in A549 cells and an IC50 < 10 µM with H1299 and
H1944 cells. It does not inhibit non-transformed cell growth.



Inhibition of cell growth by VEGFq is not due to changes in the cell cycle.



NSCLC cell invasion is decreased by 40% through treatment with VEGFq.



VEGFq is taken up into cells without transfection enhancement as early as 1 hour,
localizing in both the nucleus and cytoplasm.



VEGFq is highly stable in serum and intracellularly for longer than 96 hours.



VEGFq treatment of NSCLC cells downregulates VEGF protein expression,
decreasing activation of FLK-1 corresponding with decreased ERK and AKT
phosphorylation.



VEGFq causes a significant decrease in NSCLC cell growth in vivo.



VEGFq is highly stable and remains in NSCLC xenograft tumors for greater than
72 hours.



VEGFq preferentially localizes in xenograft tumors compared to other tissues.
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VI. RECOMMENDATIONS

Although the research performed has answered many questions regarding VEGFq
and its biological significance, there are an equal number that have arisen through the
completion of this study. Below is a list of recommendations for future experiments that
will further the knowledge of the quadruplex-forming oligonucleotide field, especially
with regards to VEGFq.
First and foremost, although it is known that it is readily taken up into cells, the
exact mechanism of this process remains uncharacterized. Since there is more VEGFq
taken up in comparison to MutVEGF, this suggests that its quadruplex secondary
structure may play a role in its uptake. By studying VEGFq’s uptake in the presence of a
quadruplex inhibitor, it can be determined if the quadruplex indeed makes it more
favorable for uptake into cells. Additionally, since its large molecular weight and highly
polar nature makes VEGFq thermodynamically impossible for passive diffusion to take
place, the discovery of either a transport protein or receptor that would facilitate its
transport or endocytosis would reveal a logical procedure for this process. A third method
of uptake could possibly involve VEGFq binding to a carrier protein that is then
transported across the plasma membrane and then disassociates from VEGFq, freeing the
oligonucleotide once inside. Discovering this uptake mechanism will not only shed light
on how quadruplex-forming oligonucleotides get inside cells to such a high degree, but it
could also teach us more about how they interact with other biomolecules.
Secondly, although it is hypothesized that VEGFq binds exclusively to the VEGF
promoter, physical evidence is still lacking that would solidify this claim. A mere
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decrease in VEGF protein expression in response to VEGFq treatment does not
necessarily prove that it binds to the promoter sequence. RT-PCR analysis of RNA
extracted from untreated and VEGFq treated cells could be used to examine the changes
in VEGF expression that may indicate that VEGFq’s effects are at the transcriptional
level. Another possible method of determining VEGFq’s transcriptional effects is known
as permanganate genomic footprinting. This method utilizes the ability of permanganate
(MnO4-) to specifically oxidize thymines in single stranded DNA, namely those present
in the transcription bubbles created by RNA polymerases. These oxidized thymines are
cleaved with piperidine, the resulting fragments are amplified using PCR primers specific
to the gene of interest, and the PCR product is run on a gel and visualized using a nucleic
acid stain such as ethidium bromide (Gilmour, 2009). The resulting bands indicate the
locations of transcriptions bubbles and subsequently, the locations of RNA polymerases
on a given gene. If the polymerases on an active gene are free to proceed, it is expected
that there will be a large number of band sizes signifying the protein’s progression along
the gene; however, VEGFq treated samples are expected to exhibit very few, short bands,
since quadruplex formation would inhibit the polymerase to proceed, indicating that
VEGFq inhibits transcription of the VEGF gene.
VEGFq could be acting through alternative mechanisms than its proposed binding
to the VEGF promoter, such as antisense binding to VEGF transcripts or through binding
to VEGF protein. It may prove to be important to elucidate VEGFq’s exact mechanism of
action to fully understand its effects. Performing an experiment similar to ChIP
(chromatin immunoprecipitation) where cell extracts are incubated with VEGFq-
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modified magnetic or agarose beads followed by mass spectrometry for proteins or
sequencing for nucleic acids, may identify the binding targets of VEGFq.
Global changes in gene expression and polymerase locations due to treatment
with VEGFq can be determined by the utilization of next generation sequencing
following the above described methods (RNA extraction, permanganate footprinting, and
ChIP). Since the completion of the human genome project, the exact sequence of our
DNA and the locations and sequences of all genes have been identified; therefore,
through the use of next generation sequencing, extracted RNA or DNA can be sequenced
and aligned to their exact locations in the genome, essentially determining their identities.
This data can be used to identify the basal levels and changes due to treatment across the
entire genome. This process can be helpful to interrogate genes that would not normally
be examined with standard single gene approaches.
RNA sequencing can also be enhanced to allow for quantitation of the number of
transcripts per cell through the use of synthetic spike-in RNA’s. These synthetic RNA’s
are comprised of specific sequences that are not present in our genome, so they will not
be aligned to any gene, but rather they will be identified separately. If the sample’s cell
number is determined prior to RNA extraction, a known number of copies of spike-in
RNA can be added to each sample prior to library construction, which will allow for the
standardization of the sequencing process across samples as well as a calculation for the
number of copies of each transcript per cell. Finally, comparing the input and sequenced
spike-in RNA copies can also serve as a sequencing efficiency check, since the two copy
numbers should be equal. Although the practice of synthetic spike-in RNA’s is relatively
new, it is clear that there are many advantages to using them (Jiang, 2011).
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The author proposes that an undeveloped procedure that combines two established
methods may prove to be the best way to answer the questions surrounding VEGFq’s
interactions. A method known as dimethyl sulfate (DMS) footprinting can be used to
mark the open N7 position of both single stranded and duplex guanines, but not guanines
associated with a neighboring guanine involved in a G-quartet where the N7 is engaged
in a hydrogen bond. Marked bases are then susceptible to heating, and following a mild
alkali treatment, creating fragments that are involved in G-quartets (Neidle, 2006). While
this may reveal where a quadruplex forms (most notably at the VEGF promoter), it does
not prove that the VEGFq that was added to cells is the one associated with the
endogenous sequence, but simply its treatment induced some sort of quadruplex
formation. Therefore, another method, known as Forster Resonance Energy Transfer
(FRET), is necessary to further examine this interaction. This method utilizes the
quantum phenomenon between two fluorophores where, when the donor and acceptor
molecules are in close enough proximity (within 10 nm), the excitation of the donor
results in the emission of the acceptor (Didenko, 2001) that can be visualized using
standard fluorescence detection methods. Additionally, if standards of known of
fluorescence and varying ODN concentrations per cell number are used, the FRET signal
can be quantified and the kinetics and efficiency of quadruplex formation can be
determined. Prior to the addition of VEGFq, extracted DNA can be fragmented (to
increase PCR efficiency) and guanines on one strand can be marked through one round of
PCR with fluorescently labeled dGTP added rather than normal dGTP. The PCR product
can then be incubated with FITC-labeled VEGFq, then undergo DMS treatment before
FRET detection. As long as the modified guanines do not inhibit quartet formation, this
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process will essentially determine if VEGFq can bind with an endogenous sequence to
form a quadruplex. Additionally, if the quadruplexes positive for FRET can somehow be
purified, these DNA fragments can be sequenced to determine their sequence and then
can be mapped to reveal their exact location in the genome. While the usage of FRET
without the DMS step may reveal other binding locations of VEGFq, the elimination of
non-quartet DNA may decrease the chance of noise due to non-specific binding. NonDMS FRET should also be examined with other molecules modified with fluorophores,
notably those identified in the ChIP experiments, to determine the cell-wide interactions
of VEGFq.
Thirdly, chemotherapy drugs and other quadruplex-forming oligonucleotides that
target other genes should be tested in combination to VEGFq to identify any sets that
exhibit synergy. Synergy is when the effect caused by the grouping of two or more agents
is greater than the sum of the effects of the individual agents. Multiple chemotherapies
are often prescribed to patients because they are synergistic and therefore work against
the cancer better together than a single agent alone. If VEGFq is found to have
synergistic effects with other drugs, it would enhance its efficacy, versatility, and
marketability as an anti-cancer agent.
Lastly, as nanotechnology continues to be developed, it is evident that it can be
useful in many fields, including medicine. If VEGFq could be coupled with
nanoparticles, such as exosomes, it is hypothesized that its efficiency would be enhanced.
Not only could uptake into tumors be enhanced, but targeting to tissue types would allow
for less waste of oligonucleotides that end up in normal cells. In fact, it has been
suggested that exosomes are capable of crossing the blood brain barrier. This would
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allow VEGFq to be delivered for the treatment of brain cancer, another disease in which
VEGF is overexpressed. Finally, both quadruplex-forming oligonucleotides and many
types of nanoparticles are easily modified to perform other functions, such as additional
drug delivery, targeting to specific tissues, or even adding fluorescent or radioactive
molecules for imaging and locating their biodistribution.
It is clear that many questions still remain in the field of quadruplex-forming
oligonucleotides; however, the anti-cancer activity and other properties that they exhibit
make them an attractive option for the treatment of cancer, justifying extensive future
study and development.
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